The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

被引：443

作者：

Yuan, Min ^{[1
,2
]}

Huang, Li-Li ^{[1
,2
]}

Chen, Jian-Hua ^{[1
,3
]}

Wu, Jie ^{[3
,4
]}

Xu, Qing ^{[1
,2
]}

机构：

[1] Tongji Univ, Dermatol Hosp, Dept Oncol, Sch Med, Shanghai 200443, Peoples R China

[2] Tongji Univ, Shanghai Peoples Hosp 10, Dept Oncol, Sch Med, Shanghai 200072, Peoples R China

[3] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK 73104 USA

[4] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA

来源：

SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2019年 / 4卷 / 1期

基金：

中国国家自然科学基金;

关键词：

EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITORS; ANTI-HER3; MONOCLONAL-ANTIBODY; NIVOLUMAB PLUS IPILIMUMAB; RECEPTOR GENE-MUTATIONS; RANDOMIZED PHASE-III; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; EGFR MUTATIONS;

D O I：

10.1038/s41392-019-0099-9

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient's tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.

引用

页数：14

共 50 条

[31] Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
Patrick R. Halliday
Collin M. Blakely
Trever G. Bivona
Current Oncology Reports, 2019, 21
[32] Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
Halliday, Patrick R.
Blakely, Collin M.
Bivona, Trever G.
CURRENT ONCOLOGY REPORTS, 2019, 21 (03)
[33] An overview of radiation therapy in the treatment of non-small-cell lung cancer
Al Hebshi, Adnan
Al Hadab, Abdulrahman
ANNALS OF THORACIC MEDICINE, 2008, 3 (06) : S89 - S96
[34] Treatment of non-small-cell lung cancer
Lavolé, A
Blanchon, F
Breton, JL
Milleron, B
REVUE DES MALADIES RESPIRATOIRES, 2004, 21 (01) : 175 - 178
[35] Targeted therapy in the treatment of non-small cell lung cancer
Shepherd, Frances A.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S13 - S14
[36] Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges
Mielgo-Rubio, Xabier
Martin, Margarita
Remon, Jordi
Higuera, Oliver
Calvo, Virginia
Jarabo, Jose Ramon
Conde, Esther
Luna, Javier
Provencio, Mariano
De Castro, Javier
Lopez-Rios, Fernando
Hernando-Trancho, Florentino
Counago, Felipe
FUTURE ONCOLOGY, 2021, 17 (30) : 4011 - 4025
[37] Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer
Stinchcombe, Thomas E.
Borghaei, Hossein
Barker, Scott S.
Treat, Joseph Anthony
Obasaju, Coleman
CLINICAL LUNG CANCER, 2016, 17 (01) : 1 - 9
[38] Targeted Therapy for Mutation-Driven Metastatic Non-Small-Cell Lung Cancer
Mileham, Kathryn F.
Ahmad, Mufti N.
Kim, Edward S.
ONCOLOGY-NEW YORK, 2019, 33 (04): : 152 - 155
[39] Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead
Ulahannan, D.
Khalifa, J.
Faivre-Finn, C.
Lee, S. -M.
ANNALS OF ONCOLOGY, 2017, 28 (12) : 2923 - 2931
[40] Molecular Pathogenesis, Organ Metastasis, and Targeted Therapy for Non-Small-Cell Lung Cancer
Abdullah, Salik
Chakraborty, Ratul
Kumkar, Pratiksha Somnath
Debnath, Biplab
Bala, Asis
JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY, 2024, 43 (03) : 13 - 38

← 1 2 3 4 5 →